Antibodies for
Immunohistochemistry
HMB-45 (HMB-45)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45153 IMPATH HMB-45 RTU M (HMB-45) 50 Tests
44334 HMB-45 RTU M (HMB-45)
7 ml Ready To Use
44688 HMB-45 0,1 M (HMB-45)
100 µl liquid Concentrated
44689 HMB-45 1 M (HMB-45)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic
Control
Melanoma
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
1
/k
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas
using H & E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms.
Anti-HMB-45 stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma. Angiomyolipoma (PEComa) is
also labeled by this product.
Melanotic Neoplasms
HMB-45
S-100
SOX-10
MART-1 Tyrosinase
MiTF
CD63
Factor XIIIa
Junctional Nevus
+
+
+
+
+
+
-
-
Interdermal Nevus
-
+
+
+
+
+
-
-
Primary Melanoma
+
+
+
+
+
+
+
-
Metastatic Melanoma
+
+
+
+
+
+
+
-
Spindle Cell Melanoma
+
+
+
+
+
+
+
-
Angiomyolipoma
+
+
+
+
-
+
+
-
Adrenal Cortical
-
+
+
-
-
-
-
Dermatofibroma
-
-
-
-
-
-
-
+
PEComa
HMB-45 MART-1 CD63
S-100 Tyrosinase SM Actin Calponin Caldesmon Desmin CD68
Angiomyolipoma
+
+
+
-
-
+
+
+
-
+
Lymphangiomyomatosis
+
+
+
-
-
+
+
+
-
-
Extrapulmonary Clear Cell
Tumor
+
+
+
+
-
+
-
-
-
-
Primary Cutaneous
PEComa
+
+
+
-
-
-
-
-
-
+/-
Pulmonary Clear Cell Sugar
Tumor
+
+
+
+/-
-
-
-
-
-
+/-
Reference
1. Gown AM, et al. A J Path. 1986; 123:195.
2. Wick MR, et al. Arch Path Lab. 1988; 112:616.
3. Leong ASY, et al. Surg Path. 1989; 2:137.
4. Abrahamsen HN, et al. Cancer. 2004 Apr 15; 100(8):1683-91.
5. Vaggelli L, et al. Tumori. 2000 Jul-Aug; 86(4):346-8.
142
